

SAPIENS INTERNATIONAL CORP N V  
Form SC 13D/A  
September 24, 2007

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**SCHEDULE 13DA**

**Under the Securities Exchange Act of 1934**

**(Amendment No.8)\***

**Sapiens International Corporation N.V.**

(Name of Issuer)

**Common Shares, € 0.01 par value**

(Title of Class of Securities)

**N7716A102**

(CUSIP Number)

**Gad Goldstein**

**Formula Systems (1985) LTD**

**3 Abba Eban Boulevard**

**Herzlia 46725, Israel**

**972-9-959-8800**

(Name, Address and Telephone Number of Person Authorized

to Receive Notices and Communications)

**September 2007**

(Date of Event which Requires Filing of this Statement)

**If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of rule 240.13d-1(e), 240.13d-1(f) or 249.13d-1(g), check the following box.**

**Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See rule 240.13d-7 for other parties to whom copies are to be sent.**

**\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.**

**The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).**

**CUSIP NO. N7716A102**

**Names of Reporting Persons.**

1. **I.R.S. Identification Nos. of above persons (entities only)**  
Formula Systems (1985) Ltd.
2. **Check the Appropriate Box if a Member of a Group (See Instructions)**  
(a)  
(b)
3. **SEC Use only**
4. **Source of funds (See Instructions)** WC
5. **Check if disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)**
6. **Citizenship or Place of Organization**  
Israel

- |   |                                 |
|---|---------------------------------|
| <b>Number of Shares<br/>Beneficially Owned by<br/>Each Reporting Person<br/>With:</b> | <b>Sole Voting Power</b>        |
|   | 7.<br>11,588,593                |
|   | <b>Shared Voting Power</b>      |
|   | 8.<br>NA                        |
|   | <b>Sole Dispositive Power</b>   |
|   | 9.<br>11,588,593                |
|   | <b>Shared Dispositive Power</b> |
|   | 10.<br>NA                       |

11. **Aggregate Amount Beneficially Owned by Each Reporting Person**  
11,588,593
12. **Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)**
13. **Percent of Class Represented by Amount in Row (11)**  
53%
14. **Type of Reporting Person (See Instructions)**  
CO

SCHEDULE 13DA DISCLOSURE

Amendment No. 7

**Item 1: Security and Issuer**

This statement relates to Common Shares, par value 0.01 euro.

The name of the Issuer is Sapiens International Corporation N.V. ( Sapiens ), a Netherlands Antilles corporation, whose principal executive offices are located at Harman House, Uxbridge, Middlesex UB8 1QQ England.

**Item 2: Identity and Background**

The name of the reporting corporation is Formula Systems (1985) Ltd. ( Formula ), which is organized under the laws of Israel.

Formula s principal business is holding and managing interests in companies that provide global IT solutions and services.

Formula s principal office is located at 3 Abba Eban Blvd.

Herzlia Pituach, Israel 46725

There are no criminal convictions or civil judgments or injunctions to report under Item 2(d) or (e) of Schedule 13D.

**Item 3: Source or Amount of Funds or Other Consideration**

1)

In September 2007 Formula completed the investment of \$6,4999,997, in return for 2,166,666 common shares of Sapiens pursuant to a private offering..

2)

In addition, between August 2006 and May 2007, Formula purchased an additional 173,652 common shares in the public market in consideration of \$251,238 in cash.

**Item 4: Purpose of Transaction**

Formula has acquired the securities of Sapiens for long term investment purposes.

Formula may from time to time acquire additional common shares of Sapiens in the public market.

Formula does not have any current plans to dispose of the securities of the issuer or to effect any other transaction described in Items 4(b) through (j) of Schedule 13D.

**Item 5: Interest in Securities of the Issuer**

Formula is the beneficial owner of 11,588,593 common shares out of total outstanding shares of 21,862,313 which represents 53% of the outstanding shares of Sapiens.

**Item 6: Contracts, Arrangements, Understandings, etc.**

NA

**Item 7: Material to Be Filed as Exhibits**

NA

**SIGNATURE**

**After reasonable inquiry and to the best of my knowledge and belief, I certify that that information set forth in this statement is true, complete and correct.**

**Date: September 24<sup>th</sup>, 2007**

**FORMULA SYSTEMS (1985) LTD.**

**By:**

**Gad Goldstein**

**President & CEO**

/s/ \_\_\_\_\_

**GAD GOLDSTEIN**

**SIGNATURE**

**After reasonable inquiry and to the best of my knowledge and belief, I certify that that information set forth in this statement is true, complete and correct.**

**Date September 24<sup>th</sup>, 2007**

**FORMULA SYSTEMS (1985) LTD.**

**By:**

**Gad Goldstein**

**President**

\_\_\_\_\_

**GAD GOLDSTEIN**